Arroven | أروفِن
Proven direction — every idea audited

← back

💊 Johnson & Johnson JNJ — $274.38

🟢 This one has been rising steadily for months. It's not in today's best ideas — we'd wait for a cheaper price before buying.

Our record on this asset

29
ideas published
22
resolved
55%
ended in profit
+3.19%
average per idea
publishedheldentryresult
2026-08-1463d$260.35 open
2026-08-0463d$254.93 open
2026-08-0363d$254.41 open
2026-07-3163d$256.35 open
2026-07-1763d$253.04 open
2026-07-1663d$249.97 open
2026-07-1621d$252.59 +2.5% (time)
2026-07-1563d$247.02 open
2026-07-1321d$255.53 +0.2% (time)
2026-07-1021d$257.95 +1.3% (time)
2026-07-0921d$260.19 -0.4% (time)
2026-07-0910d$260.19 -4.3% (stop)
2026-07-0810d$260.63 -2.8% (stop)
2026-07-0621d$264.89 -3.6% (time)
2026-07-0610d$264.89 -5.8% (stop)
2026-07-0210d$260.23 -2.5% (stop)
2026-07-0110d$255.78 -1.2% (time)
2026-06-3010d$253.25 -1.7% (time)
2026-06-2910d$259.00 -3.6% (stop)
2026-06-2221d$235.64 +8.3% (time)
2026-06-1821d$228.95 +10.4% (time)
2026-06-1810d$228.95 +15.7% (time)
2026-06-1721d$231.78 +6.8% (time)
2026-06-1621d$234.03 +7.7% (time)
2026-06-0821d$232.38 +12.0% (time)
2026-06-0810d$232.38 +3.2% (time)
2026-06-0521d$232.77 +12.0% (time)
2026-06-0410d$230.00 -0.5% (time)
2026-06-0421d$230.00 +16.8% (time)

Every idea was timestamped before its outcome was known. We publish the losers alongside the winners.

Recent news

2026-09-02 2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now The Motley Fool
2026-09-02 Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ The Motley Fool
2026-09-02 AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks Zacks Investment Research
2026-09-01 Vanguard Health Care ETF vs Simplify Health Care ETF The Motley Fool
2026-09-01 If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now Zacks Investment Research
2026-08-31 From Padcev to PF-08634404: Pfizer's Oncology Growth Push Zacks Investment Research
2026-08-31 Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel GlobeNewswire Inc.
2026-08-28 Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X? The Motley Fool

Educational information, not financial advice.